One of the most important health problems in the world today is cancer. The World Health
Organization (WHO) reported that it results in 8.9 million deaths annually. Malignant tumours …

Abstract Treatment of liver cancer and other diseases are a challenging task for the current
researchers in the pharmaceutical field. There are some physiological barriers like RES …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high
morbidity and mortality worldwide. Chemotherapy is recommended to patients with …

Hepatocellular carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat
due to long latent period before detection, multidrug resistance and severe drug-related …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and poses a
major challenge to global health due to its high morbidity and mortality. Conventional …

Background: The pathogenesis of hepatic diseases involves several cells, which
complicates the delivery of pharmaceutical agents. Many severe liver diseases affecting the …

Hepatocellular carcinoma (HCC) is most common lethal malignancy worldwide. About 80%
of liver cancer cases are attributed to the combined effects of Hepatitis B and C virus …

Background: Nanoformulation strategies that render spatial placement and temporal
delivery of drugs feasible, can be of utility in delivering the drug specifically to afflicted liver …

Hepatocellular carcinoma (HCC), due to the lack of efficient diagnostic methods and short of
available treatments, becomes the third main cause of cancer deaths. Novel treatments for …

Hepatocellular carcinoma, the most frequent solid tumor of the liver, has a very poor
prognosis, being the second most common cause of death from cancer worldwide. The …